The ultimate goal of a template is to help investigators create high quality protocols that are consistent, well organized and contain all pertinent information needed to be properly reviewed.
One tool holds a unique position among R&D informatics systems -- electronic laboratory notebooks (ELNs). ELNs both produce data and consume information and are particularly powerful.
In order to ensure a smooth development and clinical process, companies must carefully plan their activities with regard to the innovator biopharmaceutical.
Formulation techniques and technologies can easily become more habit than science, but a single technology does not work for all compounds. Each new drug is unique and deserves a fresh approach to formulation.
Biotech Millennium found that by clearly defining workflows and implementing a highly configurable notebook, it could move its entire discovery organization to a single ELN system.
A Q&A session with formulation and bioavailability experts on addressing formulation challenges for pediatric populations.
The reality is that paper is more of a habit than a requirement. AstraZeneca discovered this when they aimed to introduce ELNs to improve the efficiency of their validated workflows for GMP API manufacture.
Even with forecasting and building out a sizeable buffer inventory, clinical sites may still not always have the appropriate kits on hand to dispense to patients. Why?
Takeda Pharmaceutical Company Limited recently announced that the company will feature a total of 14 Takeda Oncology-sponsored presentations at two upcoming medical meetings: the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5 in Chicago and the 23rd Congress of the European Hematology Association (EHA), June 14-17 in Stockholm